A new analysis highlights differential long-term drug survival of commonly used biologics in psoriasis to guide treatment ...
Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced the expansion of its Scientific Advisory ...
A real world systematic review and meta-analysis found tildrakizumab improved plaque psoriasis severity and quality of life ...
Barchart on MSN
Should you chase the rally in Alumis stock today?
Alumis (ALMS) stock exploded higher on Tuesday after the biotech firm reported promising Phase 3 results for envudeucitinib, ...
Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...
Arrowhead Pharmaceuticals disclosed that its gene-silencing candidates helped people with obesity lose fat, very early ...
In both trials, envudeucitinib showed greater skin clearance than placebo on both co-primary endpoints at week 16.
A would-be psoriasis winner began taking more distinct shape in the competitive oral tyrosine kinase 2 (TYK2) inhibitor space ...
Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh ...
BioMarin Pharmaceutical Inc. / HQ: San Rafael / Condition: Phenylketonuria, or PKU / Drug: Pegvaliase-pqpz, Palynziq / ...
Explore the safety and efficacy of switching to etanercept biosimilars, backed by clinical trials and real-world evidence for ...
Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback